The 2025 Testosterone Label Change, Updated for 2026

Regulatory history is easy to flatten into a slogan. In 2025, headlines said that FDA “removed the testosterone heart warning.” That was incomplete even at the time. The agency removed specific boxed-warning language about increased major cardiovascular outcomes, added blood-pressure information and warnings, retained other safety content, and did not convert testosterone into a treatment for nonspecific aging symptoms.

The story changed again in June 2026. FDA requested removal of an age-related-hypogonadism limitation-of-use statement and revisions to prostate and benign-prostatic-hyperplasia information. A current explanation must describe both actions and distinguish a requested class-wide update from the exact approved wording in the label of the product actually in your hand.

A timeline of the regulatory changes#

In 2015, FDA required class-wide labeling changes after conflicting cardiovascular reports and concern about increasing use for low testosterone associated with aging; the agency required language about possible increased risk of heart attack and stroke and a limitation for age-related hypogonadism. It also required manufacturers to conduct a large cardiovascular-outcomes trial.

TRAVERSE supplied that trial evidence in 2023. Separate ambulatory blood-pressure-monitoring studies, required after earlier product studies raised concern, supplied class-wide blood-pressure evidence.

On February 28, 2025, FDA took four main actions:

1. Add TRAVERSE results to testosterone labels.
2. Remove language from the boxed warning about an increased risk of adverse cardiovascular outcomes.
3. Retain the limitation-of-use language for age-related hypogonadism.
4. Add product-specific blood-pressure findings and a new blood-pressure warning where one was absent.

Then, on June 18, 2026, HHS announced that FDA was requesting further revisions. The proposed changes would remove the limitation saying safety and effectiveness in men with age-related or idiopathic hypogonadism had not been established, revise prostate-cancer information, and revise warnings about benign prostatic hyperplasia. FDA's Testosterone Information page, current June 23, describes the updates. Because implementation can differ by product and supplement approval, the Drugs@FDA database remains the source for the exact current prescribing information for a named product.

What TRAVERSE actually studied#

TRAVERSE enrolled 5,246 men ages 45 to 80 who reported symptoms of hypogonadism, had two fasting testosterone concentrations below 300 ng/dL, and had preexisting cardiovascular disease or elevated cardiovascular risk. Participants were randomized to transdermal testosterone gel or placebo gel.

That population matters. It was not a trial of testosterone for people with normal concentrations, bodybuilding, general vitality, fertility treatment, women, or lower-risk young men. It also excluded some high-risk conditions, including recent acute cardiovascular events, thrombophilia, uncontrolled heart failure, and certain prostate findings.

Treatment continued for an average of about 21.7 months, with mean follow-up near 33 months. The primary endpoint was the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. It did not include every cardiovascular outcome.

A primary event occurred in 182 of 2,596 participants who received testosterone, 7.0%, and 190 of 2,602 who received placebo, 7.3%. The hazard ratio was 0.96, with a 95% confidence interval from 0.78 to 1.17. The upper bound stayed below the trial's prespecified noninferiority margin, so testosterone was noninferior to placebo for that composite.

Noninferiority rules out a loss larger than a chosen margin with stated confidence. It does not prove no difference, no harm, or cardiovascular benefit. The confidence interval remained compatible with some increase or decrease in relative hazard.

Why the boxed-warning language changed#

FDA had required the outcomes trial to address uncertainty created by observational reports, small studies, and inconsistent findings. TRAVERSE was large, randomized, placebo-controlled, and intentionally included men at elevated cardiovascular risk. Those features provided stronger evidence for the primary major-adverse-cardiovascular-event question.

After reviewing TRAVERSE, FDA concluded that the previous boxed-warning language about an increased risk of adverse cardiovascular outcomes was no longer supported. Removing that statement aligned the warning with the new randomized evidence.

The action was not a declaration that testosterone protects the heart. TRAVERSE was designed for noninferiority, not to show prevention of cardiovascular events. The result also attaches most directly to the studied gel, dose-adjustment protocol, selected population, monitoring, and follow-up.

Other signals need context. Atrial fibrillation, acute kidney injury, pulmonary embolism, and nonfatal arrhythmias requiring intervention occurred more often in the testosterone group. These were secondary or other endpoints without a multiplicity plan that allowed definitive claims for each. They are safety signals, neither proof of causality nor findings to erase because the primary endpoint passed. Rare events, and effects that take several decades to appear, require more person-time than one trial provides, which is why postmarket surveillance and further studies remain part of the evidence.

Why a blood-pressure warning was added at the same time#

The February 2025 communication reported that completed ambulatory blood-pressure-monitoring studies confirmed increased blood pressure across testosterone products. FDA therefore required product-specific information for completed studies and a new warning for products that lacked one.

Ambulatory monitoring measures blood pressure repeatedly during ordinary activity and sleep. It can detect small average changes that clinic readings miss, and a modest mean increase can have different clinical importance in someone with controlled pressure than in someone with severe hypertension or high baseline cardiovascular risk.

The simultaneous actions are not contradictory. One evidence stream addressed a composite of major cardiovascular events in TRAVERSE, another addressed blood-pressure effects across formulations, and a medicine can be noninferior for a composite over several years while still raising an important risk factor that requires monitoring. So “the cardiovascular warning was removed” is an incomplete summary: one cardiovascular claim came out of the boxed warning, and a different cardiovascular safety warning went in.

What the June 2026 request changed#

The June 2026 request revisited wording that FDA had retained in 2025, and the agency said the limitation stating that safety and effectiveness in age-related hypogonadism had not been established was no longer warranted after reviewing TRAVERSE and other evidence.

The HHS announcement also described requested prostate revisions. It said the proposed labeling would limit the contraindication to metastatic prostate cancer, update statements about prostate-cancer risk, and revise warnings about benign prostatic hyperplasia. It noted that available clinical and epidemiologic data had not generally shown increased prostate-cancer risk, while long latency and limited follow-up leave uncertainty.

For benign prostatic hyperplasia, the announcement said available trials did not demonstrate worsening in men with mild to moderate disease, but evidence remained limited for severe symptoms. Continued monitoring for severe symptomatic disease remained part of the proposed approach.

These statements need their regulatory verbs. FDA “requested” or “proposed” changes. A press release is not a substitute for checking whether the product you care about has that exact language in its newest approved label.

Limitation of use and approved indication are not synonyms#

An indication states the disease, population, and use for which a product is approved. A limitation of use narrows or qualifies that indication because evidence is absent, uncertain, or does not support a use.

Removing a limitation can change how the indication is read, but it does not necessarily create an entirely new indication. As of the FDA page current June 23, 2026, the agency states that testosterone products are approved only for men who have low testosterone with an associated medical condition, such as testicular, hypothalamic, or pituitary disease. It also states that none is approved for men with low levels who lack an associated medical condition.

This wording must be reconciled with the revised product-specific label before making a claim about a named product or use. Marketing language that equates the June request with unrestricted treatment of aging, fatigue, low mood, or gym performance goes beyond the FDA page, whoever is selling it to you. The diagnosis still requires symptoms or signs and consistently low measurements, and the companion article on testosterone assay pitfalls explains why one result is insufficient.

What the label change did not establish#

TRAVERSE did not test whether testosterone extends life, prevents heart attack, improves cognition, treats nonspecific fatigue, or benefits people with normal testosterone. Its primary conclusion was cardiovascular noninferiority in a defined population.

The trial does not generalize automatically to non-prescribed products, supraphysiologic doses, multi-drug regimens, or formulations with different pharmacokinetics. Nonmedical androgen use creates a different benefit-risk question.

The cardiovascular result also does not cancel other known effects and monitoring needs. Testosterone can raise hematocrit, suppress sperm production, affect acne and edema, change prostate-specific antigen, and interact with sleep apnea, lower urinary tract symptoms, thrombosis risk, and other conditions. Product labels differ by route and formulation.

TRAVERSE substudies answer separate questions. For example, the fracture substudy did not show fracture prevention and observed more clinical fractures in the testosterone group, and a favorable primary cardiovascular result cannot be borrowed to claim benefit for bone outcomes.

How to read any drug-label update#

Use a five-step method:

1. Identify the exact date and whether the action was requested, approved, or implemented.
2. Name the section changed: indication, limitation, contraindication, boxed warning, warning, adverse reactions, or clinical studies.
3. Read the evidence that prompted the change, including population, product, endpoint, effect estimate, confidence interval, and follow-up.
4. Read what was added at the same time, not only what was removed.
5. Check the latest product-specific label rather than relying on a class headline.

This method prevents a narrow wording change from becoming a universal safety or efficacy claim. Labels evolve because evidence evolves, and each revision answers a defined regulatory question.

Practical implications for a patient conversation#

The 2025 and 2026 actions support a more precise conversation, not a shorter one. Expect to confirm why your testosterone is low, repeat appropriately timed testing, discuss fertility goals, review cardiovascular and thromboembolic history, measure blood pressure, and consider hematocrit, prostate risk, urinary symptoms, sleep apnea, and medication interactions as clinically appropriate.

If you are already using prescribed testosterone, do not stop, increase, or change formulation on the strength of a headline alone. The clinician who prescribed it can compare the exact current label with your indication, your response, your laboratory findings, your blood pressure, and any adverse effects.

New chest pain, sudden breathlessness, one-sided weakness, fainting, or symptoms of a blood clot require urgent evaluation. These symptoms are emergencies regardless of whether a medicine's boxed-warning wording has changed.

References#

1. FDA Testosterone Information, current June 23, 2026
2. HHS and FDA June 2026 requested label updates
3. FDA February 2025 class-wide labeling changes
4. TRAVERSE cardiovascular safety trial
5. TRAVERSE prostate safety trial
6. Endocrine Society testosterone guideline
7. Drugs@FDA current labels

For your own health, talk with your clinician.*